Table 1 SEs involved in cancer.

From: Super-enhancer function and its application in cancer targeted therapy

TF binding with SE

Target molecular/signal pathway

Tumor type

Tumorigenesis

Therapy

Ref.

TCF4

c-MYC/Wnt

Colorectal cancer

√

 

35

ESR

ERA/Channel oncogenic signal pathway

Breast cancer

√

 

20,51

BRD4

C-MYC

Unascertained

√

√

21,57,58,59,60

TAL1

MYB

Leukemia

√

√

34

GATA2

EVI1

AML

√

 

68,70,71

GATA3

LMO1

Neuroblastoma

√

 

33

NFE2L2, CEBPB

MYC

Lung adenocarcinoma

√

 

72

MYB/TGFBR3

MYB/RAD51B

Adenold cystic carcinoma

√

√

73

  1. AML acute myeloid leukemia, BRD4 bromodomain-containing protein 4, ERA estrogen receptor alpha, ESR estrogen receptor, EVI1 ecotropic virus integration site-1, SE super-enhancer, TAL1 T-cell acute lymphoblastic leukemia transcription factor 1, TCF4 transcription factor 4, TF transcription factor, TGFBR3 transforming growth factor beta receptor III.
Back to article page